Literature DB >> 31883279

Higher densities of tumour-infiltrating lymphocytes and CD4+ T cells predict recurrence and progression of ductal carcinoma in situ of the breast.

Aye Aye Thike1,2, Xiaoyang Chen1,3, Valerie Cui Yun Koh1, Nur Diyana Binte Md Nasir1, Joe P S Yeong1,4, Boon Huat Bay3, Puay Hoon Tan1,2,3,5.   

Abstract

AIMS: Host immunity influences cancer progression and therapeutic response. We investigated the potential of tumour-infiltrating lymphocytes (TILs) around ductal carcinoma in situ (DCIS) in predicting recurrence and progression. METHODS AND
RESULTS: CD4, CD8, programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in DCIS from 198 patients was determined by immunohistochemistry. We correlated disease-free survival (DFS), clinicopathological parameters and biomarker expression with TIL density and CD4/CD8 ratio. High TIL density was associated with high nuclear grade (P < 0.001), DCIS PD-L1 expression (P = 0.008), TIL PD-L1 expression (P < 0.001), oestrogen (ER) negativity (P < 0.001), progesterone (PR) negativity (P < 0.001), human epidermal growth factor receptor 2 (HER2) positivity (P = 0.002) and triple negativity (P = 0.001). TIL PD-L1 expression was associated with triple-negative DCIS (P = 0.028). TIL density was associated with molecular subtypes (P < 0.001). High CD4+ T cell density was associated with high nuclear grade (P = 0.001), microinvasion (P = 0.037), ER negativity (P < 0.001), PR negativity (P = 0.001), HER2 positivity (P = 0.004), triple negativity (P = 0.023) and PD-L1 expression in TILs (P < 0.011). High CD4/CD8 ratio was associated with PD-L1 expression in DCIS (P = 0.035) and TILs (P < 0.001). DCIS with higher TIL density disclosed worse DFS (P = 0.012) and was affirmed with multivariate analysis [95% confidence interval (CI) = 1.109-2.554, hazard ratio (HR) = 1.683, P = 0.014]. Poorer DFS for ipsilateral invasive recurrence was found for DCIS with higher CD4+ T cell density (P = 0.006) or CD4/CD8 ratio (P = 0.02), confirmed by multivariate analysis for the former (95% CI = 1.369-10.196, HR = 3.736, P = 0.01) and latter (95% CI = 1.311-7.935, HR = 3.225, P = 0.011).
CONCLUSION: DCIS with higher TIL density was associated with poorer prognostic parameters and predicted recurrence, while both CD4+ T cell density and CD4/CD8 ratio were associated with both recurrence and ipsilateral invasive recurrence.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990DCISzzm321990; CD4; PD-L1; progression; recurrence; tumour-infiltrating lymphocytes

Year:  2020        PMID: 31883279     DOI: 10.1111/his.14055

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  12 in total

Review 1.  Ductal Carcinoma in Situ: Molecular Changes Accompanying Disease Progression.

Authors:  Gemma M Wilson; Phuong Dinh; Nirmala Pathmanathan; J Dinny Graham
Journal:  J Mammary Gland Biol Neoplasia       Date:  2022-05-14       Impact factor: 2.698

Review 2.  Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

Authors:  Anna K Casasent; Mathilde M Almekinders; Charlotta Mulder; Proteeti Bhattacharjee; Deborah Collyar; Alastair M Thompson; Jos Jonkers; Esther H Lips; Jacco van Rheenen; E Shelley Hwang; Serena Nik-Zainal; Nicholas E Navin; Jelle Wesseling
Journal:  Nat Rev Cancer       Date:  2022-10-19       Impact factor: 69.800

Review 3.  Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2.

Authors:  Julia Solek; Jedrzej Chrzanowski; Adrianna Cieslak; Aleksandra Zielinska; Dominika Piasecka; Marcin Braun; Rafal Sadej; Hanna M Romanska
Journal:  Biomedicines       Date:  2022-05-03

Review 4.  Immune microenvironment in different molecular subtypes of ductal breast carcinoma.

Authors:  Mona Sadeghalvad; Hamid-Reza Mohammadi-Motlagh; Nima Rezaei
Journal:  Breast Cancer Res Treat       Date:  2020-10-03       Impact factor: 4.872

5.  Identification and validation of the prognostic value of cyclic GMP-AMP synthase-stimulator of interferon (cGAS-STING) related genes in gastric cancer.

Authors:  Kui-Sheng Yang; Chuan-Qi Xu; Jian Lv
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

6.  Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ.

Authors:  Fei-Fei Xu; Sai-Fang Zheng; Cheng Xu; Gang Cai; Shu-Bei Wang; Wei-Xiang Qi; Chao-Fu Wang; Jia-Yi Chen; Cao Lu
Journal:  Oncoimmunology       Date:  2021-03-18       Impact factor: 8.110

7.  Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast.

Authors:  Huiqing Jia; Peng Zhao; Zhaoxu Chen; Guanqun Wang; Xianning Dong; Xiaoming Xing; Xiaohua Tan; Chengqin Wang
Journal:  Breast Cancer Res Treat       Date:  2022-03-08       Impact factor: 4.872

Review 8.  Harnessing the Immunogenic Potential of Gold Nanoparticle-Based Platforms as a Therapeutic Strategy in Breast Cancer Immunotherapy: A Mini Review.

Authors:  Xiao-Yang Chen; Lin-Yue Lanry Yung; Puay Hoon Tan; Boon Huat Bay
Journal:  Front Immunol       Date:  2022-03-31       Impact factor: 7.561

9.  Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast.

Authors:  Sunil S Badve; Sanghee Cho; Xiaoyu Lu; Sha Cao; Soumya Ghose; Aye Aye Thike; Puay Hoon Tan; Idris Tolgay Ocal; Daniele Generali; Fabrizio Zanconati; Adrian L Harris; Fiona Ginty; Yesim Gökmen-Polar
Journal:  Cancers (Basel)       Date:  2022-08-13       Impact factor: 6.575

10.  The Prognostic Role of CD73/A2AR Expression and Tumor Immune Response in Periampullary Carcinoma Subtypes.

Authors:  Dina Sweed; Mohammad Taha; Sara Abd Elhamed; Asmaa Shams El Dein Mohamed
Journal:  Asian Pac J Cancer Prev       Date:  2022-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.